CD8A and non-small cell lung carcinoma: In conclusion, our retrospective study showed for the first time that combining CD8+ TILs and PD-L1 assessment seems to outperform CD8+ TILs or PD-L1 alone as a prognostic marker in NSCLC and as predictive signature of ICI response.